Allogene Therapeutics Announces Q2 Investor Conference Participation
Allogene Therapeutics(ALLO) Newsfilter·2024-04-09 12:30SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor conferences in the second quarter of 2024. Canaccord Genuity Horizons in Oncology Virtual ConferenceMonday, April 15, 202412:00pm PT/3:00pm ET JPM Securities Life Sciences Conference Tuesday, May 14, 2024 ...